Viatris EBITDA Margin 2010-2025 | VTRS

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Viatris (VTRS) over the last 10 years. The current EBITDA margin for Viatris as of March 31, 2025 is .
Viatris EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2025-03-31 $14.33B $2.73B 19.03%
2024-12-31 $14.74B $2.90B 19.70%
2024-09-30 $15.05B $2.53B 16.79%
2024-06-30 $15.24B $2.76B 18.12%
2024-03-31 $15.36B $3.27B 21.30%
2023-12-31 $15.43B $3.51B 22.73%
2023-09-30 $15.47B $3.99B 25.77%
2023-06-30 $15.60B $4.11B 26.37%
2023-03-31 $15.80B $4.33B 27.40%
2022-12-31 $16.26B $4.64B 28.54%
2022-09-30 $16.73B $4.65B 27.77%
2022-06-30 $17.19B $4.76B 27.70%
2022-03-31 $17.65B $4.76B 26.96%
2021-12-31 $17.89B $4.47B 25.00%
2021-09-30 $17.17B $3.87B 22.55%
2021-06-30 $15.60B $3.28B 21.03%
2021-03-31 $13.76B $2.56B 18.62%
2020-12-31 $11.95B $2.01B 16.79%
2020-09-30 $11.51B $2.75B 23.92%
2020-06-30 $11.50B $2.76B 24.02%
2020-03-31 $11.63B $2.81B 24.17%
2019-12-31 $11.50B $2.74B 23.78%
2019-09-30 $11.39B $2.76B 24.21%
2019-06-30 $11.29B $2.80B 24.83%
2019-03-31 $11.25B $2.89B 25.67%
2018-12-31 $11.43B $3.02B 26.38%
2018-09-30 $11.59B $3.12B 26.90%
2018-06-30 $11.72B $3.04B 25.94%
2018-03-31 $11.87B $3.25B 27.41%
2017-12-31 $11.91B $3.24B 27.23%
2017-09-30 $11.94B $3.09B 25.87%
2017-06-30 $12.01B $2.64B 22.01%
2017-03-31 $11.61B $2.46B 21.21%
2016-12-31 $11.08B $2.22B 20.06%
2016-09-30 $10.30B $2.20B 21.33%
2016-06-30 $9.94B $2.74B 27.58%
2016-03-31 $9.75B $2.56B 26.28%
2015-12-31 $9.43B $2.49B 26.44%
2015-09-30 $9.02B $2.29B 25.37%
2015-06-30 $8.41B $2.06B 24.48%
2015-03-31 $7.88B $1.88B 23.86%
2014-12-31 $7.72B $1.92B 24.86%
2014-09-30 $7.45B $1.77B 23.81%
2014-06-30 $7.13B $1.61B 22.60%
2014-03-31 $6.99B $1.68B 24.06%
2013-12-31 $6.91B $1.65B 23.91%
2013-09-30 $6.82B $1.63B 23.86%
2013-06-30 $6.86B $1.67B 24.30%
2013-03-31 $6.85B $1.62B 23.73%
2012-12-31 $6.80B $1.66B 24.35%
2012-09-30 $6.61B $1.64B 24.77%
2012-06-30 $6.38B $1.54B 24.09%
2012-03-31 $6.27B $1.56B 24.88%
2011-12-31 $6.13B $1.52B 24.73%
2011-09-30 $6.03B $1.35B 22.39%
2011-06-30 $5.81B $1.28B 22.08%
2011-03-31 $5.61B $1.17B 20.94%
2010-12-31 $5.45B $1.14B 20.99%
2010-09-30 $5.37B $1.10B 20.51%
2010-06-30 $5.28B $0.93B 17.57%
2010-03-31 $5.18B $0.90B 17.45%
2009-12-31 $5.09B $0.92B 18.14%
Sector Industry Market Cap Revenue
Medical Medical Services $10.857B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $147.077B 27.58
CVS Health (CVS) United States $83.011B 10.32
Elevance Health (ELV) United States $78.142B 10.08
Cencora (COR) United States $57.628B 20.05
DiDi Global (DIDIY) China $23.768B 25.25
Natera (NTRA) United States $22.306B 0.00
Labcorp Holdings (LH) United States $21.229B 17.22
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $13.751B 0.00
Solventum (SOLV) United States $13.128B 13.90
CochLear (CHEOY) Australia $12.788B 0.00
ICON (ICLR) Ireland $12.281B 11.42
Revvity (RVTY) United States $12.070B 20.77
Medpace Holdings (MEDP) United States $9.434B 25.06
Avantor (AVTR) United States $9.336B 13.56
Sonic Healthcare (SKHHY) Australia $8.582B 0.00
HealthEquity (HQY) United States $8.405B 36.81
Charles River Laboratories (CRL) United States $8.038B 15.75
Caris Life Sciences,�Inc (CAI) United States $6.772B 0.00
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $5.024B 29.58
BrightSpring Health Services (BTSG) United States $3.667B 33.65
Sotera Health (SHC) United States $3.375B 19.18
Surgery Partners (SGRY) United States $2.855B 37.12
Alignment Healthcare (ALHC) United States $2.647B 0.00
Concentras Parent (CON) United States $2.621B 15.15
Organon (OGN) United States $2.605B 2.77
GeneDx Holdings (WGS) United States $2.480B 95.51
Ardent Health (ARDT) United States $2.041B 8.70
Progyny (PGNY) United States $2.024B 44.55
PACS (PACS) United States $1.949B 0.00
Premier (PINC) United States $1.767B 13.41
GoodRx Holdings (GDRX) United States $1.750B 35.00
Teladoc Health (TDOC) United States $1.546B 0.00
Establishment Labs Holdings (ESTA) $1.329B 0.00
Pediatrix Medical (MD) United States $1.160B 8.82
CareDx (CDNA) United States $1.149B 17.94
Ryman Healthcare (RYHTY) New Zealand $0.970B 0.00
Agilon Health (AGL) United States $0.956B 0.00
AMN Healthcare Services Inc (AMN) United States $0.846B 7.92
QDM (QDMI) Hong Kong, SAR China $0.846B 290.00
Nutex Health (NUTX) United States $0.653B 9.89
Embecta (EMBC) United States $0.627B 4.22
InnovAge Holding (INNV) United States $0.567B 0.00
SBC Medicals (SBC) United States $0.552B 0.00
LifeMD (LFMD) United States $0.544B 0.00
Sonida Senior Living (SNDA) United States $0.486B 0.00
Auna S.A (AUNA) Luxembourg $0.471B 10.60
Omada Health (OMDA) $0.461B 0.00
So-Young (SY) China $0.389B 0.00
Enhabit (EHAB) United States $0.375B 30.88
COMPASS Pathways (CMPS) United Kingdom $0.348B 0.00
Performant Healthcare (PHLT) United States $0.338B 0.00
Beauty Health (SKIN) United States $0.257B 0.00
Oncology Institute (TOI) United States $0.256B 0.00
DocGo (DCGO) United States $0.153B 25.00
Pheton Holdings (PTHL) China $0.134B 0.00
Sera Prognostics (SERA) United States $0.104B 0.00
KindlyMD (NAKA) United States $0.080B 0.00
Ascend Wellness Holdings (AAWH) United States $0.079B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
IceCure Medical (ICCM) Israel $0.059B 0.00
Basel Medical Group (BMGL) Singapore $0.055B 0.00
ModivCare (MODV) United States $0.054B 0.00
Biodesix (BDSX) United States $0.045B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.037B 0.00
OSR Holdings (OSRH) United States $0.023B 0.00
Intelligent Bio Solutions (INBS) United States $0.013B 0.00
BioNexus Gene Lab (BGLC) $0.011B 0.00
Co-Diagnostics (CODX) United States $0.008B 0.00
SeaStar Medical Holding (ICU) United States $0.007B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00